Mass Tort brief
Daubert Gates, Bellwether Clashes, and Bankruptcy Stays
Federal judges test plaintiff science in GLP-1 and Depo-Provera as toxic tort dockets cross 206,000 active claims.
Mass Tort
Judge Marston's Daubert ruling will decide the fate of 4,000 GLP-1 injury lawsuits — determining whether Novo Nordisk and Eli Lilly face multi-billion dollar jury trials.
BackgroundMultidistrict litigation consolidates thousands of federal product liability lawsuits before a single judge to streamline discovery and pre-trial motions. Rule 702 Daubert hearings evaluate whether scientific experts use reliable, peer-reviewed methodologies before presenting injury claims to civil juries.
- The hearing focused on whether scientific studies reliably demonstrate that medications including Ozempic, Wegovy, and Mounjaro cause severe gastroparesis and bowel blockages.
- More than 4,000 consolidated lawsuits accuse manufacturers Novo Nordisk and Eli Lilly of providing inadequate safety warnings on product labels.
- Exclusion of plaintiff general causation experts would result in summary dismissal for thousands of claims, while admission clears the path for bellwether jury trials.
Mass Tort
The Supreme Court petition targets the Texas Two-Step at its core — aiming to stop solvent corporations from freezing injury jury trials in bankruptcy court.
BackgroundThe Texas Two-Step allows a solvent corporation to divide into two entities, placing product liability lawsuits into an undercapitalized affiliate that immediately files for Chapter 11. The maneuver pauses all active jury trials through an automatic bankruptcy stay while the parent company continues profitable operations.
- Claimants argue the procedural tactic unconstitutionally denies sickened workers their Seventh Amendment right to jury trials in Article III courts.
- The high-court petition arrives amid long-running legal proceedings involving Georgia-Pacific's Bestwall subsidiary and Johnson & Johnson's talc maneuvers.
- A decision by the Supreme Court to take the case could fundamentally alter restructuring playbooks for corporate defendants facing massive mass tort liabilities.
Mass Tort
With 4,588 assault claims pending, the October bellwether trial will determine whether Uber faces an unsustainable trial calendar or negotiates a global settlement.
BackgroundThe passenger assault multidistrict litigation before Judge Charles Breyer in San Francisco alleges Uber failed to institute rigorous driver screening and monitoring systems. Bellwether trials serve as test cases to help plaintiffs and defendants calculate realistic global settlement parameters.
- Attorneys submitted cross-motions in limine and contested jury instructions for the third federal trial testing platform liability for driver violence.
- The docket comprises 4,588 federal claims brought by passengers who suffered sexual violence from contracted drivers during rides.
- Prior bellwether tests yielded mixed outcomes, including an $8.5M jury verdict and a defense win, raising the financial stakes of the upcoming October trial.
Mass Tort
Judge Rodgers' preemption hearing puts non-settling Depo-Provera claims to the test — pressuring holdouts toward Pfizer's November 30 settlement deadline.
BackgroundPfizer negotiated a private master settlement agreement in July 2026 expected to resolve roughly 80% of pending meningioma claims. However, thousands of claimants remain outside the agreement, prompting the court to establish strict litigation tracks for remaining claims.
- The court reviewed scientific expert challenges while establishing a November 30 settlement registration deadline administered by BrownGreer.
- Pfizer argues that federal drug labeling regulations preempt state failure-to-warn claims for long-approved hormonal contraceptives.
- The judge selected replacement pilot test cases to expedite statute-of-limitations defenses across more than 6,400 active filed lawsuits.
Mass Tort
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
